1:30 PM SIGN-IN • 2:00 PM - 3:30 PM
BANDOL 2 (NEW WYNN SPACE)
CE: Updates in Myelofibrosis: The Significance of JAK Inhibitors in Therapy
Myelofibrosis is a rare blood cancer with a high rate of mortality within several years of diagnosis. The identification of the certain mutations, including JAK2, CALR, and MPL, has helped to open the treatment landscape to targeted therapies. JAK (Janus-associated kinase) inhibitors are changing the therapeutic landscape from traditional chemotherapy for symptom control and agents to address anemia, and are showing that by stemming disease progression, patients’ lives may be extended. This program will focus on evidence and nuances to available JAK inhibitors and discuss agents in the pipeline for myelofibrosis. Additionally, cumulative direct and indirect costs associated with myelofibrosis and its acute impact on patients’ quality of life will be addressed.